The ReSPonD trial - rivastigmine to stabilise gait in Parkinson’s disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson’s disease who have fallen

Peer Review reports

Original Submission
4 Nov 2013	Submitted	Original manuscript
7 Nov 2013	Author responded	Author comments - Emily Henderson
Resubmission - Version 2
7 Nov 2013	Submitted	Manuscript version 2
Publishing
11 Nov 2013	Editorially accepted
3 Dec 2013	Article published	10.1186/1471-2377-13-188

Back to article page